hVIVO builds on position of strength in challenge trials

Respiratory syncytial virus causes the common cold, for which there is no effective cure.

hVIVO Is seeing interest for challenge models in COPD and asthma as well as RSV

Drug development services provider hVIVO PLC (LON:HVO) has its strongest sales pipeline for several years, according to executive chairman Trevor Phillips.

At the start of October, the human disease model specialist won new contracts worth £9mln for two respiratory syncytial virus (RSV) human challenge studies.

WATCH: hVIVO PLC on track to be profitable in 2019 says CEO Phillips

That followed an £11.9mln RSV study agreement signed in September, again with an unnamed group.

Contagious, respiratory syncytial virus causes the common cold, for which there is no effective cure.

The £11.9mln contract will start to contribute from October and throughout 2019.

“We are experiencing a lot of interest from leading pharmaceutical companies for the development of new challenge models in RSV, asthma and COPD and we expect to be able to convert a number of these into contracts,” said Phillips.

Revenues in the half year to June rose to 26% to £4.9mln, while losses dropped to £5.3mln from £9.1mln as R&D spending was reined back, something that will continue in 2019, Phillips said.

Cash holdings at the half year were £10.7mln.

FLU-v vaccine nails phase II trial

hVIVO got a major boost last summer when flu vaccine FLU-v performed strongly in a phase II trial, and the new year got off to a good start when it received confirmation that the study achieved its primary endpoint.

The delay was because US regulators needed more time to assess the data as the initial analysis was based on results from a less sensitive assay, which sometimes misses the presence of influenza virus.

“The more sensitive assay, routinely utilised by NIAID to assess the presence of virus, identified more cases of influenza infection than had originally been determined, resulting in the achievement of statistical significance,” said executive chairman Phillips.

READ: hVIVO's flu vaccine set for phase III trials

Currently, flu vaccines have to be redesigned every year as the flu virus evolves rapidly.

One of the major plus-points for FLU-v is that it offers long-lasting protection against a broad spectrum of influenza which hVIVO believes could be given to a much broader population.

“[That] would be a significant step forward, and a potential future blockbuster in terms of sales.”

Profitable in 2019

Talks are now underway to find a partner or even sell Imutex, the joint venture with SEEK that is developing FLU-v.

Other options include a licensing agreement or a non-dilutive funding arrangement with a collaborator to run the phase III development and study for FLU-v.

hVIVO and SEEK have a good idea of how they would design the phase III trial which they will discuss with regulatory authorities at their upcoming meetings.

Imutex is also developing a vaccine (AGS-v) for mosquito-borne diseases and first data from a Phase 1 safety study is due by the end of the year.

Phillips said it has been a good start to 2018 with the group building on its lead position in viral challenge-based human disease models.

“We aim to create a stronger range of services that, alongside our operational efficiencies, will enable hVIVO to be profitable and generate cash from its operations in 2019.”

Challenge trials save time

During a challenge trial, a person’s symptoms, bloodstream, genes are all measured to understand what happens over a course of time when you have an infection such as flu.

People are monitored from healthy to the moment they are infected and subsequently recover, with many samples taken at multiple data points.

The idea is to test if therapies work or give an early indication if a drug will be efficacious.

Phillips says ethics and safety are the prime considerations, which limits the areas they can be used but where appropriate challenge trials are very effective.

COPD or asthma studies can cost £25mln and take two years, whereas hVIVO can carry it out in 5-8 months for £8mln.

Phillips believes hVIVO is one of only a few companies with the model for this type of human challenge study.

Expanding the range of product to boost the revenue stream is the next objective but Phillips is confident enough to predict the company will be in profit by the end of 2019.

“It’s a very specialised offering that we are very good at.

“Profitability next year is the target. A service business like hVIVO that has been around for some time has to start generating cash."

Quick facts: hVIVO PLC

Price: - -

Market: LSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...



hVIVO PLC gearing up for Phase III trial of its flu vaccine FLU-v

Trevor Phillips, executive chairman of hVIVO PLC (LON:HVO), caught up with Proactive Investors after reporting good responses in a phase IIb trial of their new treatment FLU-v. The trial hit both its primary and secondary endpoints with a reduction in influenza infection rates and...

on 21/6/18

4 min read